Research ArticleClinical Studies
Open Access
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease
YUTARO KUBOTA, QINGHONG HAN, CHIHIRO HOZUMI, NORIYUKI MASAKI, JUN YAMAMOTO, YUSUKE AOKI, TAKUYA TSUNODA and ROBERT M. HOFFMAN
Anticancer Research May 2022, 42 (5) 2567-2572; DOI: https://doi.org/10.21873/anticanres.15734
YUTARO KUBOTA
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
3Division of Internal Medicine, Department of Medical Oncology, Showa University School of Medicine, Tokyo, Japan;
QINGHONG HAN
1AntiCancer Inc., San Diego, CA, U.S.A.;
CHIHIRO HOZUMI
1AntiCancer Inc., San Diego, CA, U.S.A.;
4Anticancer Japan, Narita, Japan
NORIYUKI MASAKI
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
JUN YAMAMOTO
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
YUSUKE AOKI
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
TAKUYA TSUNODA
3Division of Internal Medicine, Department of Medical Oncology, Showa University School of Medicine, Tokyo, Japan;
ROBERT M. HOFFMAN
1AntiCancer Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
In this issue
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease
YUTARO KUBOTA, QINGHONG HAN, CHIHIRO HOZUMI, NORIYUKI MASAKI, JUN YAMAMOTO, YUSUKE AOKI, TAKUYA TSUNODA, ROBERT M. HOFFMAN
Anticancer Research May 2022, 42 (5) 2567-2572; DOI: 10.21873/anticanres.15734
Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease
YUTARO KUBOTA, QINGHONG HAN, CHIHIRO HOZUMI, NORIYUKI MASAKI, JUN YAMAMOTO, YUSUKE AOKI, TAKUYA TSUNODA, ROBERT M. HOFFMAN
Anticancer Research May 2022, 42 (5) 2567-2572; DOI: 10.21873/anticanres.15734
Jump to section
Related Articles
- No related articles found.
Cited By...
- Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
- [11C] Methionine-PET Imaging as a Cancer Biomarker for Methionine Addiction and Sensitivity to Methionine-restriction-based Combination Chemotherapy
- Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer
- Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis
- Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
- Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model
- Oral Installation of Recombinant Methioninase-producing Escherichia coli into the Microbiome Inhibits Colon-cancer Growth in a Syngeneic Mouse Model
- Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model
- Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet